-

09:34:21 AM

IMAB Stock News

IMAB - I-Mab

07/22/22 8:00 AM

Nasdaq : IMAB

clinical trial

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in China has been treated with

RHEA-AI

neutral

07/18/22 8:00 AM

Nasdaq : IMAB

conferencesclinical trial

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from

RHEA-AI

neutral

07/06/22 8:00 AM

Nasdaq : IMAB

conferences

I-Mab to Host 2022 R&D Day

I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and

RHEA-AI

neutral

06/23/22 8:00 AM

Nasdaq : IMAB

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in

RHEA-AI

very positive

06/15/22 10:37 AM

Nasdaq : IMAB, MOR

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner

RHEA-AI

very positive

06/15/22 8:41 AM

Nasdaq : IMAB, MOR

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner

RHEA-AI

very positive

06/14/22 4:01 PM

Nasdaq : MOR, IMAB

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

RHEA-AI

very positive

06/14/22 5:19 AM

Nasdaq : IMAB

clinical trial

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also...

RHEA-AI

neutral

06/09/22 7:00 AM

Nasdaq : IMAB

Ferring Announces New Collaboration for Development of Olamkicept

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease and related inflammatory conditions. Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and...

RHEA-AI

very positive

06/07/22 12:49 AM

Nasdaq : IMAB

clinical trial

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced top-line results from the KEYNOTE-899 phase 1 b/2 clinical trial of GX-I7 in combination with pembrolizumab. Genexine presented these data in a poster presentation...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IMAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.i-mabbiopharma.com/en
Security nameI-Mab - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2021
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About I-Mab

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.